Genentech terminates $3B Adaptimmune cell therapy pact same week as staff cuts
fiercebiotech.com/biotech/one-da…

Top BIO lobbyist swiftly departs after BIOSECURE reversal. Karuna leaders launch new venture after BMS buyout. Orna snags top Kite exec as CMO. 🪂🪜fiercebiotech.com/biotech/chutes…

Novartis may have emerged victorious from a bidding war for MorphoSys, but a peek into the deal negotiations reveals that the Swiss pharma would have been happier if it could have walked away with one specific asset. fiercebiotech.com/biotech/novart…

J&J continues investment in rare maternal-fetal diseases, this time with Rallybio and the goal of raising awareness $JNJ $RLYB fiercebiotech.com/biotech/jj-ral…

Novartis is adding another weapon to its arsenal of oncology therapies, paying Arvinas $150 million upfront for rights to a phase 3-ready protein degrader that could treat a wide range of prostate cancer patients.
fiercebiotech.com/biotech/novart…

2023 was the first time that Chinese biotechs out-licensed more assets than they in-licensed. But rising national security concerns risk dampening a scorching-hot business. fiercebiotech.com/biotech/chines…

A session at the American Association for Cancer Research annual meeting posed a key question: Are cancer vaccines ready for prime time?
fiercebiotech.com/biotech/aacr-2…

The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a startup run by former bluebird bio execs is emerging from stealth to reveal its solutions to the industry.
fiercebiotech.com/research/forme…

A piece of the latest comeback strategy slotted into place when the biotech revealed a written agreement with the FDA on the design of a phase 3b ALS trial. fiercebiotech.com/biotech/brains…

Voting closes in #FierceMadness : The Best Biotech Name Tournament Championship at 11 am ET!!! Make your pick between Werewolf Therapeutics and Obsidian Therapeutics now!!

Another fun one from Annalee Armstrong on the ground at AACR, this time as a solar eclipse occurs. fiercebiotech.com/biotech/aacr-2…

The sun is shining in San Diego, but you wouldn’t really know it from the cavernous exhibit hall of the AACR annual meeting. Annalee Armstrong takes us behind the scenes of the conference here. fiercebiotech.com/biotech/aacr24…

Merck & Co. has signed a $280M deal to acquire Abceutics, a University at Buffalo startup, in hopes of improving ADC safety. fiercebiotech.com/biotech/merck-…

Regeneron’s multiple myeloma medicine linvoseltamab, which was accepted for priority review at the FDA in February, is showing durability in the latest data drop from a phase 1/2 test. fiercebiotech.com/biotech/aacr-r…

Sanofi is laying off employees around the globe after a 'full pipeline reprioritization,' R&D chief Houman Ashrafian told staff in an email Thursday that was obtained by Fierce Biotech. fiercebiotech.com/biotech/sanofi…

Lonza nabs new CEO after acquiring Roche site. Amgen R&D leader jumps to Acadia. Three C-suite leaders depart I-Mab. 🪂🪜fiercebiotech.com/biotech/chutes…

As new cancer vaccines—led by Moderna and Merck’s mRNA-4157—near pivotal trial readouts, the FDA’s vaccines czar Peter Marks said the agency is ready to review the shots despite AI-related unknowns.
fiercebiotech.com/biotech/were-o…

Merck KGaA is the latest biopharma to swell its pipeline with further ADC potential this week, inking a deal worth up to $1.4 billion with Caris should any candidate get to market. fiercebiotech.com/biotech/merck-…

Genmab is betting $1.8 billion to buy ProfoundBio and gain control of a midphase ADC that could compete against AbbVie’s Elahere. fiercebiotech.com/biotech/genmab…

The biggest M&A deal of Q1 was Gilead's $4.43 billion CymaBay Therapeutics buy. The largest—and first—IPO was CG Oncology's $380 million raise. fiercebiotech.com/biotech/fierce…